I-VASC was founded in 2015 with the goal of introducing its patented medical device for minimally invasive treatment of varicose veins to the global market.
I-VASC has proven its ability to successfully move from a concept idea to a viable product.
I-VASC team is committed to make Velex™ and other application of its Mt VESS™ platform technology commercially available for HCPs and patients around the world
I-VASC was founded in 2015 with the goal of introducing its patented Empty Vein Ablation (EVA) technology for the minimally invasive treatment of varicose veins to the global market.
I-VASC successfully moved from a conceptual idea to an innovative and fully validated product, by obtaining in 2021 the CE Mark certification for its VELEX™ system, catheter and handle
I-VASC Team is committed to make VELEX™ and E.V.A. procedure commercially available to for patients and doctors around the world, and to develop new applications for its technology platform
The Empty Vein Ablation (EVA) technology is protected by a IP portfolio of several patents granted in all relevant global geographies
The I-VASC technology has received the endorsement of several global Key Opinion Leaders in vascular therapies
Six patents granted and Seven pending
Four different series of prototypes developed
Key Opinion Leader endorsement
Positive in ex vivo and in vivo pre-clinical testing